Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.72 |
| ▸ | BRAF | P15056 | 11/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655828 | 0.89 | BRAF (0.63) | TLR8BRAFKDM4ENPC1RAB9A | |
| SCHEMBL11472378 | 0.89 | MAP2K1 (0.65) | BRAFKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL4656020 | 0.87 | BRAF (0.80) | TLR8BRAFKDRMAPK13LIMK1 | |
| SCHEMBL3164329 | 0.86 | BRAF (0.82) | TLR8BRAFKDM4EALDH1A1HPGD | |
| SCHEMBL3176935 | 0.86 | TLR8 (0.82) | TLR8BRAFKDM4EALDH1A1MAP2K1 | |
| SCHEMBL4656785 | 0.86 | BRAF (0.59) | TLR8BRAFKDM4ENPC1RAB9A | |
| SCHEMBL3161762 | 0.85 | BRAF (0.58) | TLR8BRAFKDM4ENPC1RAB9A | |
| SCHEMBL3169712 | 0.85 | BRAF (0.61) | TLR8BRAFKDM4ENPC1RAB9A | |
| SCHEMBL4655935 | 0.85 | BRAF (0.66) | TLR8BRAFKDRMAPK13LIMK1 | |
| SCHEMBL11351081 | 0.84 | BRAF (0.58) | TLR8BRAFKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | claimed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | claimed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | claimed |
| US-4178449-A | Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1979-12-11 | — | — | US | claimed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-4236005-A | ANTIANXIETY | AMERICAN CYANAMID COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| US-4178449-A | Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1979-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | AZI2, CDK2, TPMT | TLR8 4131/4885BRAF 148/4885KDM4E 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.